1. Academic Validation
  2. Effects of Cycloleucine in the Nucleus Accumbens Septi on the Elevated plus Maze Test in Rats

Effects of Cycloleucine in the Nucleus Accumbens Septi on the Elevated plus Maze Test in Rats

  • Neuropsychobiology. 2020;79(3):191-197. doi: 10.1159/000505069.
Augusto P I Gargiulo 1 Andrés Acuña 1 Mercedes M L Gargiulo 1 Ángel J M Gargiulo 1 Marcos C J Gargiulo 1 Gustavo C Baiardi 2 Sergio Mora 3 José Vicente Lafuente 4 Esteban Romanowicz 1 Adriana I Landa 1 Manuel A Guevara 1 Pascual Ángel Gargiulo 5
Affiliations

Affiliations

  • 1 Laboratory of Neurosciences and Experimental Psychology, CONICET, Department of Pathology, Faculty of Medical Sciences, National University of Cuyo, Mendoza, Argentina.
  • 2 Laboratory of Neuropharmacology, Institute of Biological and Technological Research (IIBYT-CONICET), National University of Córdoba, Faculty of Chemical Sciences, Catholic University of Córdoba, Córdoba, Argentina.
  • 3 Program of Molecular and Clinical Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago de Chile, Chile.
  • 4 Laboratory of Clinical and Experimental Neurosciences (LaNCE), Department of Neuroscience, University of the Basque Country (UPV/EHU)-Barrio Sarriena, Leioa, Spain.
  • 5 Laboratory of Neurosciences and Experimental Psychology, CONICET, Department of Pathology, Faculty of Medical Sciences, National University of Cuyo, Mendoza, Argentina, [email protected].
Abstract

Introduction: In recent years, an important number of studies have emphasized the psychopharmacological actions of cycloleucine (1-aminocyclopentanecarboxylic acid) acting on the NR1 subunit (glycine allosteric site) of NMDA (N-methyl-D-aspartic acid) receptor. We studied the effects of its injection in an anxiety test.

Methods: The elevated plus maze test was used. Male rats bilaterally cannulated into the nucleus accumbens septi (NAS) were employed. Rats were divided into 5 groups that received either 1 µL injections of saline or cycloleucine (0.5, 1, 2, or 4 µg) 15 min before testing.

Results: Time spent in the open arm was significantly increased by cycloleucine treatment with all doses (1 and 2 µg, p < 0.05; 0.5 and 4 µg, p < 0.01), like number of extreme arrivals (0.5 and 1 µg, p < 0.05; 2 µg, p < 0.01; and 4 µg, p < 0.001). Open arm entries were increased by the highest dose only (4 µg, p < 0.01).

Discussion/conclusion: Present results show no difference between all doses in the time spent in the open arm, suggesting an indirect, noncompetitive action of the drug. The increase in extreme arrivals and open arm entries suggests a dose influence in these parameters. We conclude that cycloleucine influence on the NMDA receptors within NAS leads to anxiolytic-like effects and behavioral disinhibition, which once more confirms the involvement of NAS in anxiety processing.

Keywords

Accumbens; Anxiety; Cycloleucine; NR1 subunit.

Figures
Products